PI11334 N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine (CAS No.: 231278-20-9)

N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine (CAS No.: 231278-20-9) Description

The compound, with the molecular formula C21H14ClFIN3O, is a pharmaceutical intermediate featuring a multi-functional aromatic structure. Its halogen substituents adjust the electron distribution, allowing targeted reaction control during synthetic procedures. The powder form supports accurate weighing and handling, while standard analytical techniques confirm its structural attributes and purity, making it suitable for drug development and related synthetic applications.

N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine (CAS No.: 231278-20-9) Applications

1.         Pharmaceutical Research
   - Used as a synthetic building block in the development of enzyme inhibitors to achieve specific molecular interactions by leveraging its defined halogen functionalities.
   - Applied as an intermediate for API synthesis to facilitate subsequent functional group modifications, thereby enhancing structural diversity.

2.         Chemical Manufacturing
   - Utilised as a reagent in heterocyclic synthesis to construct complex molecules, providing predictable reaction behaviour through its aromatic backbone.

N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine (CAS No.: 231278-20-9) Packing

The compound is packed in moisture-proof, anti-static containers and sealed under inert conditions to prevent contamination. Each package is designed to protect the powder from environmental moisture and particulate ingress. The packaging is constructed from chemically resistant materials and includes detailed batch information. Customised packaging options such as vacuum sealing or secondary containment may be requested based on specific storage requirements.

Additional Information

Pharmaceutical intermediates like this compound play a crucial role in multi-step organic syntheses. Their precise molecular specifications allow for targeted modifications that are essential in developing advanced therapeutic agents. Understanding the influence of halogen substitution on reactivity is vital in designing synthesis pathways that achieve high selectivity and yield.

In the broader context of medicinal chemistry, the characteristics of heterocyclic intermediates significantly impact the efficiency of pharmaceutical production. Detailed structural analysis and impurity profiling are standard practices that uphold material integrity and facilitate consistent outcomes in drug development research.